CTx-001 (Complement Therapeutics)

N/A

Report date: 2026/03/26 14:46:48

Base Information

Drug NameCTx-001 (Complement Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionComplement receptor type 1 modulators
TargetsComplement receptor type 1
Therapy Area/IndicationsGeographic AtrophyMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Manchester
China Registration ClassN/A

Develop Information

Active CompaniesComplement Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsGeographic AtrophyMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A